Pricing Log in Create free account
Friday 6 November 2026 Export LNSR’s income statement to Excel — free account

LENSAR, Inc.

LNSR Healthcare Medical Devices

LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024.

Revenue
+18.4%
EPS
+291.7%
Free cash flow
+96.8%

Quarter to June 2026, against a year earlier

5.37 0.13 −2.36%
Market cap
$67.6M
P/E
3.9×
Fwd P/E
6.9×
Dividend yield
—
F-score
3/9
Altman Z
−2.84
Beneish M
−4.30
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 19.98%

Capital & Financial Ratios $m

Size
Market Cap 67.57
Revenue ttm 60.26
Net income ttm 34.70
Free cash flow ttm (7.40)
Net debt Q (13.56)
Valuation
P/E 3.89
Forward P/E 6.87
Price / sales 1.13
Forward P/S Powerpack
Price / FCF 0.00
Price / book 4.55
Financial health
Current ratio Q 2.39 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (107.37)
Growth
Revenue growth Q +18.37% (above 0%: growing)
Operating income growth Q +133.93% (above 0%: growing)
EPS, this year +100.35% (at or above 15%: strong)
EPS, next year A −2,350.00% (below 0%: weak)
Revenue, next year A +4.90%
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 1.1×; over the ten years it ranged from −0.1× in 2021 to 2.6× in 2025.
P/S against its own 10 years 25.54%
10-year low 10-year high
P/B against its own 10 years 83.91%
10-year low 10-year high
EV/Sales against its own 10 years 39.92%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 24 22 18 14
Receivables 4 6 6 6
Inventory 16 11 22 25
Other — — — —
46 42 47 47
2023 2024 2025 Q'26
Payables 4 6 19 11
ST’ Debt — — — —
Other — — 10 —
12 15 41 20

Compound Annual Growth %

10y 5y 3y
Sales — 17.24% 18.23%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY22 Estimate −0.88 Actual −0.67

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY21 −0.59 −0.47 Beat by 0.12
Q3 FY21 −0.59 −0.65 Miss by 0.06
Q4 FY21 −0.60 −0.41 Beat by 0.19
Q1 FY22 −0.88 −0.67 Beat by 0.21

EPS $

Mar Jun Sep Dec Year
’26 0.00 0.10 — — —
’25 (2.32) (0.15) (0.31) (0.12) (2.87)
’24 (0.19) (0.79) (0.13) (1.61) (2.73)
’23 (0.40) (0.81) 0.21 (0.35) (1.31)
’22 (0.67) (0.67) (0.39) (0.24) (1.96)
’21 (0.56) (0.47) (0.65) (0.41) (2.09)
’20 (3.44) (4.20) (0.64) (0.78) (4.28)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 13 16 — — —
’25 14 14 14 16 58
’24 11 13 14 17 53
’23 8 12 10 12 42
’22 9 8 8 10 35
’21 7 8 8 11 34
’20 6 5 7 8 26
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) 0 — — —
’25 (7) (5) (4) 1 (15)
’24 (5) (4) 3 4 (2)
’23 (7) (2) 0 0 (10)
’22 (3) (3) (5) (5) (15)
’21 (5) (1) (2) (1) (9)
’20 (6) (5) 0 (2) (14)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) 0 — — —
’25 (7) (5) (4) 1 (15)
’24 (5) (4) 3 4 (2)
’23 (7) (2) 0 (1) (10)
’22 (3) (3) (5) (5) (15)
’21 (5) (1) (2) (1) (9)
’20 (6) (6) 0 (2) (14)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 24 31 26 34 35 42 53 58 60 +13.3% 61 73 94 +17.0%
Gross margin, % — — 44.07 43.33 53.35 51.75 56.44 50.06 48.33 46.41 48.34 +2.3 pt
EBT — — (13) (15) (20) (20) (20) (14) (31) (34) 35 +15.4%
EBT margin, % — — (51.55) (48.01) (74.95) (56.88) (56.32) (34.11) (58.71) (58.66) 57.57 (7.1) pt
Net income — 0 (13) (15) (20) (20) (20) (14) (31) (34) 35 n/m
Per share, $
Per share, $ Revenue — — 22.79 28.53 5.71 3.68 3.48 3.84 4.64 4.89 4.90 (19.7%)
Earnings — — — (13.70) (4.28) (2.09) (1.96) (1.31) (2.73) (2.87) 1.42 (22.9%)
Cash flow — — (1.76) (11.77) (2.98) (0.96) (1.46) (0.88) (0.20) (1.24) (0.59) (4.9%)
Capex — — (3.04) (1.95) (0.07) (0.04) (0.01) (0.02) (0.01) (0.01) (0.01) (58.1%)
Free cash flow — — (4.80) (13.72) (3.05) (0.99) (1.47) (0.90) (0.21) (1.25) (0.60) (17.5%)
Book value — — (19.13) (28.55) 14.54 5.85 4.13 3.05 0.42 (2.18) 1.21 (26.7%)
Shares, m — — 1 1 5 9 10 11 12 12 12 +41.2%
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.89 0.0
P/S — — 2.53 2.53 1.27 1.63 0.78 1.05 1.92 2.38 1.13 1.8
P/B — — 0.97 0.97 0.50 1.02 0.66 1.33 21.18 0.00 4.55 3.3
EV/Sales — — 1.16 1.16 (0.03) 0.89 0.55 0.63 1.62 2.18 1.01 1.0
EV/FCF — — (1.63) (1.63) 0.06 (3.31) (1.29) (2.69) (35.72) (8.54) (8.19) (6.8)
Cash, $m
Cash, $m Operating cash flow — — (2) (13) (14) (9) (15) (10) (2) (15) (7) +34.3%
Capex — — (3) (2) 0 0 0 0 0 0 0 (40.8%)
Free cash flow — — (5) (15) (14) (9) (15) (10) (2) (15) (7) +16.5%
Balance, $m
Balance, $m Working capital — — 4 9 50 36 22 35 27 6 27 +6.1%
Net debt — — 3 16 (41) (32) (15) (24) (22) (18) (14) n/m
Shareholders’ equity — — (20) (31) 67 55 42 33 5 (26) 15 +3.5%
Returns, %
Returns, % ROA — — (97.24) (46.22) (34.80) (26.93) (32.56) (22.93) (46.22) (49.78) 49.58 +47.5 pt
ROIC — — 0.00 0.00 (43.45) (52.85) (46.18) (81.61) 0.00 0.00 (379.01) 0.0 pt
ROE — — 55.06 57.46 (107.89) (32.11) (41.12) (38.14) (164.03) 324.05 (851.75) +269.0 pt
People
People Employees — — — 75 100 110 110 130 140 150 — +12.2%
Revenue/emp, $m — — 0.00 0.41 0.26 0.31 0.32 0.32 0.38 0.39 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

LENSAR, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NYXH Nyxoah SA $82.6M — (loss-making) — (loss-making) +486.62% (above 0%: growing) n/m +4.01% (above 0%: growing) 59.73% (268.25%) Compare
SERA Sera Prognostics, Inc. $82.1M — (loss-making) — (loss-making) +162.50% (above 0%: growing) n/m −12.79% (below 0%: shrinking) 0.00% (21,159.52%) Compare
ECOR electroCore, Inc. $79.3M — (loss-making) — (loss-making) +11.52% (above 0%: growing) n/m −69.10% (below 0%: shrinking) 88.47% (16.06%) Compare
LUCD Lucid Diagnostics Inc. $79.3M — (loss-making) — (loss-making) +26.74% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 1.97% (868.45%) Compare
OM Outset Medical, Inc. $77.0M — (loss-making) — (loss-making) +14.15% (above 0%: growing) n/m −61.85% (below 0%: shrinking) 40.69% (36.52%) Compare
HYPR Hyperfine, Inc. $72.7M — (loss-making) — (loss-making) +44.81% (above 0%: growing) n/m +13.43% (above 0%: growing) 50.72% (216.93%) Compare
MBOT Microbot Medical Inc. $71.9M — (loss-making) — +1,047.62% (above 0%: growing) n/m −98.72% (below 0%: shrinking) (266.80%) (2,567.63%) Compare
LNSR LENSAR, Inc. $67.6M 3.9× 6.9× +18.37% (above 0%: growing) n/m +96.81% (above 0%: growing) 59.27% 12.94%
COCH Envoy Medical, Inc. $55.0M — (loss-making) — (loss-making) +57.14% (above 0%: growing) n/m −22.44% (below 0%: shrinking) (269.70%) (8,389.39%) Compare
Median of peers $78.1M — — +50.98% — −17.61% 21.33% (568.35%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 23 June 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.34m 3.19m 331.34
2024 1.58m 3.00m 254.70
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

LENSAR, Inc. (LNSR) Latest News

20 Aug

Impact 4 · · The Motley Fool transcript

13 Aug

Impact 4 ·
Impact 3 · · MarketBeat
Impact 3 · · Moby transcript
Impact 3 · earnings

4 Jun

Impact 4 · · Simply Wall St.

1 Jun

Impact 3 · · The Motley Fool transcript
Impact 3 · · The Motley Fool transcript

8 May

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

21 Apr

Impact 4 ·

4 Apr

Impact 4 · · Simply Wall St.

3 Apr

Impact 4 · · GuruFocus.com

1 Apr

Impact 4 · · Moby

31 Mar

Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat

17 Mar

Impact 4 · · medtechdive.com

16 Mar

Impact 4 · · Business Wire
Impact 4 · · GlobeNewswire

25 Feb

Impact 5 · · GlobeNewswire

6 Nov

Impact 4 ·

7 Aug

Impact 4 · · GlobeNewswire

24 Mar

Impact 4 ·

28 Feb

Impact 4 ·

27 Feb

Impact 4 · · GlobeNewswire

25 Jan

Impact 3 · · Simply Wall St.

20 Dec

Impact 4 ·

9 Nov

Impact 4 ·

8 Nov

Impact 4 ·
stockrow.com/LNSR · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com